| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 150, 455-459, Copyright © 1997 by American Society for Investigative Pathology
REGULAR ARTICLES |
RR Tremblay, D Deperthes, B Tetu and JY Dube
Department of Medicine, Laval University, Quebec, Canada.
The development of monoclonal antibodies directed against prostatic kallikrein hK2 prompted us to evaluate its content, along with that of hK3 (prostate-specific antigen), in human prostate carcinoma. Seventy tumors categorized according to the M.D. Anderson Hospital classification (grade I to IV) were analyzed by immunohistochemistry. The staining intensity or the kallikrein content of benign prostatic hyperplasia glandular tissue (used as control) and of grade I tumors appeared similar. In grade II to IV tumors, histochemical data revealed highly variable hK2 or hK3 content in approximately 25% of tumors. Such patterns are consistent with a current observation related to heterogeneity of prostate tumors. In addition, a few tumors did not express hK3 (n = 3), hK2 (n = 3), or both (n = 3), indicating that some growth patterns of prostatic neoplasia are associated with a lack of secretion or storage of hK3 or hK2 for immunodetection. This statement also appears relevant to metastases. It was interesting to note that 4% of hK3-negative tumors had detectable hK2. Because of the importance of hK3 as a serum marker of prostate disorder, this study addresses for the first time the question of the relative importance of both hK3 and hK2 in the immunohistochemical diagnosis of prostatic tumors. We conclude that hK2 may add new information to prostate cancer diagnosis and characterization.
This article has been cited by other articles:
 |
|
 |
|
  T L Veveris-Lowe, M G Lawrence, R L Collard, L Bui, A C Herington, D L Nicol, and J A Clements Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells Endocr. Relat. Cancer, September 1, 2005; 12(3): 631 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Xie, Z. Luo, K. M. Slawin, and D. M. Spencer The EZC-Prostate Model: Noninvasive Prostate Imaging in Living Mice Mol. Endocrinol., March 1, 2004; 18(3): 722 - 732. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Meng, A. Shan, L. Jin, and C. Y. F. Young The Expression of a Variant Prostate-specific Antigen in Human Prostate Cancer Epidemiol. Biomarkers Prev., March 1, 2002; 11(3): 305 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Stephan, K. Jung, M. Lein, P. Sinha, D. Schnorr, and S. A. Loening Molecular Forms of Prostate-specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 2000; 9(11): 1133 - 1147. [Abstract] [Full Text]
|
|
|
|
 |
|
 D.-C. Yu, G. T. Sakamoto, and D. R. Henderson Identification of the Transcriptional Regulatory Sequences of Human Kallikrein 2 and Their Use in the Construction of Calydon Virus 764, an Attenuated Replication Competent Adenovirus for Prostate Cancer Therapy Cancer Res., April 1, 1999; 59(7): 1498 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bourgeois, M. Brillard-Bourdet, D. Deperthes, M. A. Juliano, L. Juliano, R. R. Tremblay, J. Y. Dube, and F. Gauthier Serpin-derived Peptide Substrates for Investigating the Substrate Specificity of Human Tissue Kallikreins hK1 and hK2 J. Biol. Chem., November 21, 1997; 272(47): 29590 - 29595. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
